Colorectal cancer
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) Patients with histologically confirmed or clinically suspected advanced CRC (aCRC) 2) Planned to receive systemic chemotherapy for aCRC 3) KRAS exon 2 (codon12, 13) mutations were or will be determined 4) Presence or ability to acquire sufficient DNA for target sequencing 5) Written informed consent was obtained
Exclusion criteria
Exclusion criteria: 1) Patient is judged by the investigator to be inappropriate for study participation for any reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency or characteristics of cancer genome alterations such as KRAS minor, BRAF, NRAS, PIK3CA in CRC | — |
Secondary
| Measure | Time frame |
|---|---|
| Association between each cancer genome alterations and clinicopathological characteristics or prognosis,Quality of the specimen contributing to gene analysis | — |
Countries
Japan
Contacts
National Cancer Center Hospital East Gastrointestinal Oncology Division